VKTX stock is trading at $33.61 — we rate Viking Therapeutics a Buy with a $99.50 average analyst price target, implying 196% upside as 25 covering analysts model Phase 3 readouts for its GLP-1/GIP obesity candidate VK2735. The VKTX stock price prediction 2026 thesis pivots entirely on VK2735: a twice-monthly oral and subcutaneous dual agonist that has matched or beaten Eli Lilly’s tirzepatide on weight-loss magnitude in Phase 2, and that enters pivotal Phase 3 VANQUISH-1 and VANQUISH-2 trials in 2026.
Key VKTX Stock Data — April 2026
| Metric | Value |
|---|---|
| Ticker / Exchange | VKTX / NASDAQ |
| Current Price | $33.61 |
| 52-Week Range | $21.40 – $99.41 |
| Market Cap | $3.74B |
| EPS (TTM) | -$0.95 |
| Revenue (TTM) | $0 (pre-commercial) |
| Cash & Equivalents | $808M |
| Debt | $0 |
| Analyst Consensus | Buy (17 Buy / 1 Hold / 0 Sell) |
| Average Price Target | $99.50 |
| Target Range | $35 – $125 |
| Implied Upside | +196% |
| Next Catalyst | Q1 2026 earnings, April 29 |
Table of Contents
- Key VKTX Stock Data — April 2026
- What Is Viking Therapeutics and Why VKTX Stock Matters
- VKTX Stock Recent Performance: From $99 Peak to $33
- VK2735 Obesity Drug: The $99.50 Target Driver
- Bullish and Bearish Analyst Opinions on Viking Therapeutics
- VKTX Stock Price Prediction 2026: Analyst Targets
- VK2735 Mechanism of Action and Dosing Advantages
- Viking’s MASH and Second Pipeline Optionality
- Bottom Line on VKTX Stock Price Prediction 2026
- VKTX Stock Price Prediction 2026 FAQs
What Is Viking Therapeutics and Why VKTX Stock Matters
Viking Therapeutics (NASDAQ: VKTX) is a San Diego-based clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. The company has no commercial products and generated zero revenue in fiscal 2025, but it commands a $3.74B market capitalisation entirely on the strength of its pipeline — anchored by VK2735, a dual GLP-1/GIP receptor agonist positioned to compete directly with Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound) in the $150B obesity-therapy market.
VKTX stock matters to biotech investors because it offers something almost unique in 2026: a fully de-risked Phase 2 dataset in obesity, a dual oral-and-injectable formulation strategy, $808M in cash and zero debt, and a shareholder base that has already priced in roughly 75% pullback from the March 2024 all-time high of $99.41. The question driving every VKTX stock model is whether the market is currently handicapping the VK2735 Phase 3 program correctly, or whether the 196% consensus upside reflects analyst conviction that the 2024 peak undershot rather than overshot fair value.
VKTX Stock Recent Performance: From $99 Peak to $33
VKTX stock has delivered a textbook biotech round-trip. After the February 2024 VENTURE Phase 2 readout showed 14.7% placebo-adjusted weight loss at 13 weeks — numerically superior to Eli Lilly’s Zepbound at the same time point — shares rocketed from $13 to $99.41 in 28 trading days. The subsequent 18 months saw VKTX stock retrace to the $30-$40 range as four things happened in sequence: Lilly launched head-to-head trial data, Novo Nordisk confirmed its next-generation amycretin in Phase 1, multiple obesity biotechs (Terns, Structure) reported competitive data, and the broader biotech sector entered a funding winter that compressed every pre-commercial multiple.
Over the trailing twelve months, VKTX stock is down 52%, underperforming the XBI biotech ETF by 31 percentage points. Over the trailing three months, shares have traded in a tight $28-$38 range, reflecting a market that has already absorbed the competitive disappointment and now waits for Phase 3 execution. For context, Viking now trades at roughly 4.6x net cash — a level typically reserved for binary-event biotechs where the Street assigns low probability to first pivotal trial success. That valuation is why the average analyst target sits at $99.50: the Street, in aggregate, disagrees with the market.
VK2735 Obesity Drug: The $99.50 Target Driver
VK2735 is the central VKTX stock catalyst for 2026 and 2027. Viking is running two Phase 3 pivotal trials: VANQUISH-1 enrolls approximately 4,500 adults with obesity on the subcutaneous weekly formulation, and VANQUISH-2 enrolls a similar cohort on the once-daily oral formulation. First patient dosing began in Q1 2026, with interim data expected in H2 2027 and topline readouts in 2028. An orally bioavailable GLP-1/GIP agonist that matches injectable efficacy would be a category-defining asset — which is why Morgan Stanley, Cantor Fitzgerald and H.C. Wainwright all use peak annual sales estimates above $8B in their discounted-cash-flow models supporting price targets north of $100.
The bear case on VKTX stock is well-rehearsed: Lilly and Novo have multi-year head starts, manufacturing scale, payer contracts, and a combined $40B+ per year in current revenue to fund next-generation assets. If Lilly’s retatrutide (triple agonist) or Novo’s CagriSema combination delivers superior efficacy before VKTX reaches market, VK2735 becomes a follower asset in a commoditised class rather than a disruptor. Viking’s $808M in cash, however, funds operations through 2028 without dilution — and Viking has publicly stated it is open to strategic partnerships, which has kept takeout speculation bid as a secondary thesis underneath the VKTX stock price prediction 2026 conversation.
Bullish and Bearish Analyst Opinions on Viking Therapeutics
| Bullish Case | Bearish Case |
|---|---|
| VK2735 Phase 2 showed 14.7% placebo-adjusted weight loss at 13 weeks — matches or beats tirzepatide’s 13-week profile | Lilly and Novo Nordisk have 3-4 year commercial head start with entrenched payer relationships |
| Oral GLP-1 formulation could capture 30-40% of patients unwilling to inject — $50B+ subsegment | Next-generation competitors (retatrutide, CagriSema, orforglipron) may match or exceed VK2735 efficacy before launch |
| $808M cash with zero debt funds operations through 2028 without dilution risk | Pre-revenue biotech with all-or-nothing binary Phase 3 risk profile through 2028 |
| Takeout valuation could exceed $150/share given strategic scarcity of de-risked GLP-1/GIP assets | Obesity pricing power may compress as Medicare negotiations and biosimilars arrive post-2028 |
| Consensus $99.50 target from 25 analysts implies 196% upside from current levels | Trailing 52-week performance -52% signals structural market skepticism about competitive moat |
VKTX Stock Price Prediction 2026: Analyst Targets
The VKTX stock price prediction 2026 sell-side distribution is unusually tight on direction (17 of 18 analysts rate Buy) but unusually wide on magnitude ($35 to $125 target range — a 3.6x spread). The highest targets come from analysts modelling peak annual VK2735 sales of $10B+ in a scenario where the oral formulation captures meaningful share from Lilly’s injectable franchise. The lowest targets come from analysts who discount pipeline value heavily for competitive erosion risk.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Cantor Fitzgerald | Louise Chen | Overweight | $125 |
| H.C. Wainwright | Douglas Tsao | Buy | $119 |
| Morgan Stanley | Jeffrey Hung | Overweight | $112 |
| Oppenheimer | Jay Olson | Outperform | $105 |
| Bank of America | Jason Zemansky | Buy | $100 |
| Stifel | Annabel Samimy | Buy | $95 |
| Barclays | Peter Lawson | Overweight | $88 |
| JPMorgan | Tessa Romero | Neutral | $40 |
| Jefferies | Michael Yee | Hold | $35 |
The median $99.50 target assumes VANQUISH-1 interim safety data in H2 2027 confirms no tolerability drop-off versus Phase 2, and that Viking enters 2028 with a fully enrolled Phase 3 program and a partnered or independent commercial launch path. Investors weighing the VKTX stock price prediction 2026 outlook should treat the catalyst calendar as the primary driver: Q1 2026 earnings on April 29 will confirm cash runway and Phase 3 enrollment cadence; Q4 2026 should deliver VANQUISH-1 interim safety look; and the 2027 investor day is where Viking is expected to outline commercial strategy. For broader stock coverage, see our related analyses of Eli Lilly (LLY), Novo Nordisk (NOVO), and Amgen (AMGN).
VK2735 Mechanism of Action and Dosing Advantages
Understanding the VKTX stock price prediction 2026 bull case requires understanding why VK2735’s molecular design could carry a differentiation premium versus the existing GLP-1/GIP franchise. VK2735 is a dual agonist targeting both the GLP-1 receptor (driving insulin secretion and appetite suppression) and the GIP receptor (amplifying GLP-1 effects while protecting against nausea and hypoglycaemia). The molecule’s half-life of approximately 142 hours supports weekly subcutaneous dosing, comparable to tirzepatide’s 5-day half-life. Critically, VK2735’s oral formulation — targeting once-daily dosing — uses a proprietary permeation enhancer that achieved 4-6% oral bioavailability in Phase 1, within the range required for commercial-scale tablet manufacturing.
The Phase 2 VENTURE trial readout in February 2024 demonstrated 14.7% placebo-adjusted weight loss at 13 weeks — a result that matched tirzepatide at the same timepoint and exceeded semaglutide. Importantly, the discontinuation rate due to adverse events was 5.8% in VK2735 arms versus 4.3% in placebo, suggesting tolerability comparable to leading GLP-1s. If Phase 3 VANQUISH trials replicate this profile at 52 and 72 weeks — the durations at which tirzepatide delivered 22.5% absolute weight loss — VK2735 enters the market as a genuine category peer rather than a follower.
Viking’s MASH and Second Pipeline Optionality
A frequently underappreciated element of the VKTX stock investment case is the second-pipeline optionality that sits underneath VK2735. Viking’s VK2809 is a selective thyroid hormone receptor beta (TR-beta) agonist in Phase 2 development for metabolic dysfunction-associated steatohepatitis (MASH) and primary hypercholesterolemia. The mechanism competes directly with Madrigal Pharmaceuticals’ Rezdiffra — the first FDA-approved MASH therapy — and Phase 2 readouts in 2024 showed VK2809 delivered statistically significant reductions in hepatic fat content and LDL cholesterol with a clean tolerability profile.
Wall Street analysts assign $10-20 of implicit per-share value to VK2809 in sum-of-the-parts VKTX stock models, reflecting the MASH market’s addressable population (10-15 million US adults) and Madrigal’s own valuation as a single-asset MASH play. Viking also holds VK0214 (X-linked adrenoleukodystrophy, in Phase 1b) as a rare-disease orphan opportunity. None of these second-line assets is currently being priced with any meaningful weight into VKTX stock — meaning that even a conservative Phase 3 outcome for VK2735 could leave significant pipeline optionality that unlocks as VK2809 progresses toward a potential 2027 pivotal readout.
Bottom Line on VKTX Stock Price Prediction 2026
VKTX stock price prediction 2026 analysis reduces to a single question: does the Street’s 196% consensus upside reflect realistic Phase 3 expectations or analyst optimism that survived the 2024 peak? The weight of evidence favours the bullish interpretation — Phase 2 data matched tirzepatide, the balance sheet funds operations through 2028 without dilution, and takeout optionality provides a secondary support. But the binary risk profile is real: a single Phase 3 safety signal or a competitive clinical readout from Lilly or Novo would compress VKTX stock toward the $15-$20 cluster. The position should be sized accordingly — no more than 2-4% of portfolio equity for retail investors, paired with explicit stops near $25 and disciplined rebalancing above $60. The $99.50 consensus target is achievable; the path there is non-linear.
VKTX Stock Price Prediction 2026 FAQs
What is the VKTX stock price target for 2026?
The average VKTX stock price target across 25 covering analysts is $99.50, with a high of $125 (Cantor Fitzgerald) and a low of $35 (Jefferies). Consensus rating is Buy, with 17 Buy ratings, 1 Hold, and 0 Sell ratings as of April 2026.
Why is VKTX stock down from its 2024 peak?
VKTX stock fell from $99.41 in March 2024 to current levels near $33.61 because (1) Lilly and Novo Nordisk launched competing GLP-1/GIP agonists at commercial scale, (2) multiple competitive obesity assets (retatrutide, CagriSema, orforglipron) reported positive Phase 2 data, and (3) the biotech sector entered a 2024-2025 funding winter that compressed pre-commercial multiples across the board.
When will Viking Therapeutics report VK2735 Phase 3 data?
Viking’s Phase 3 VANQUISH-1 (subcutaneous) and VANQUISH-2 (oral) trials began dosing in Q1 2026. Interim safety data is expected H2 2027, with topline efficacy readouts in 2028 and potential NDA submission in 2028-2029 pending positive outcomes.
Is VKTX stock a buy in 2026?
VKTX stock carries a consensus Buy rating with 196% implied upside to the $99.50 average target. However, the stock is a pre-revenue biotech with binary Phase 3 risk through 2028, $808M cash runway with zero debt, and meaningful competitive pressure from Lilly and Novo Nordisk. Suitable only for risk-tolerant investors with exposure to binary biotech outcomes.
Could Viking Therapeutics be acquired?
Viking has publicly stated it is open to strategic partnerships, and Wall Street speculation has consistently floated potential acquirers including Pfizer, Merck, AstraZeneca, and Amgen — all of whom lack a late-stage dual GLP-1/GIP obesity asset. Takeout valuations in comparable biotech M&A (Horizon, Seagen, Morphic) suggest premiums of 30-70% above standalone DCF.
What is VK2735’s dosing schedule compared to tirzepatide?
VK2735 is being developed in two formulations: a once-weekly subcutaneous injection (comparable dosing cadence to Eli Lilly’s tirzepatide and Novo’s semaglutide) and a once-daily oral tablet using a proprietary permeation-enhancer technology. The oral formulation is the differentiator — roughly 20-30% of obesity patients globally express a preference for oral dosing over injection, a subsegment that Lilly’s oral orforglipron and Novo’s oral semaglutide target but neither has fully penetrated. A successful oral VK2735 would position Viking Therapeutics uniquely in that subsegment.
How much cash does Viking Therapeutics have?
Viking Therapeutics closed fiscal 2025 with $808M in cash and cash equivalents, zero long-term debt, and a trailing twelve-month cash burn of approximately $165M driven by Phase 3 trial initiation costs. That implies a cash runway of approximately 4.9 years at current spend, or through approximately 2029 — meaningfully beyond the projected 2028 Phase 3 topline readout for VK2735. The capital position materially de-risks the VKTX stock price prediction 2026 thesis because it removes dilution risk through the key catalyst window.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.